LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.
“This distribution agreement represents continued momentum in our international commercial expansion efforts and, together with our recently announced expansion into Hong Kong and Macau, marks four new territories entered into Asia Pacific in the past month,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Improving the quality of care for patients at risk of sepsis is a critical global health initiative and we are proud to offer a solution to advance patient care by supplying our culture-independent diagnostics to our distributor partners in Malaysia and Indonesia. We are excited to grow with our new partners as we form long-lasting relationships.”
The execution of this exclusive distribution agreement further expands T2 Biosystems’ commercialization in the Asia Pacific region. A study from Malaysia found that sepsis was the most common diagnosis leading to intensive care unit (ICU) admission and the in-hospital mortality rate in the ICU for sepsis was over 50%. In Indonesia, a study from a tertiary care hospital found that 18.5% of patients admitted to the hospital had sepsis and patients admitted to the intensive care unit with sepsis had a mortality rate of 68%. The introduction of the T2Dx Instrument and sepsis test panels into Malaysia and Indonesia will allow rapid detection of certain sepsis-causing pathogens and antibiotic resistance genes, in hours instead of days, enabling clinicians to achieve targeted therapy, faster.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about global commercial expansion and international strategy, and the potential for strong growth in the region, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
- Montclair Pediatric Dentistry Sets a New Standard in Compassionate Pediatric Dental Care Across the Bay Area - May 9, 2025
- Boys & Girls Clubs of America Celebrates Its Esteemed Alumni Hall of Fame Class - May 9, 2025
- Conifer Gutter Service Unveils Dependable Solutions for Year-Round Home Protection - May 9, 2025
